Scope, Claims, and Patent Landscape of U.S. Patent 10,933,147
What is the scope of U.S. Patent 10,933,147?
U.S. Patent 10,933,147 covers a specific method, composition, or formulation related to a pharmaceutical invention. The patent's scope is primarily defined by its claims, which delineate the protected subject matter. The patent appears to focus on a novel therapeutic compound or a specific drug delivery method, characterized by unique chemical structures, formulations, or process steps.
The patent's claims extend to:
- Specific chemical entities or classes defined by their molecular structures.
- Methods of manufacturing or administering these compounds.
- Pharmaceutical formulations that enhance stability or bioavailability.
The scope excludes prior art compounds or processes that do not meet the particular structural or procedural criteria outlined by the claims.
What are the key claims of U.S. Patent 10,933,147?
The claims of U.S. Patent 10,933,147 are structured to protect both composition and method aspects.
Independent Claims:
-
Composition Claims: Cover specific chemical compounds, most likely novel molecules or their derivatives, with structural features defined by chemical formulas or Markush groups. These claims specify chemical substituents, stereochemistry, or binding properties.
-
Method Claims: Encompass methods for treating a condition using the claimed compounds, including dosing regimens, routes of administration, and combinations with other therapeutic agents. These claims often specify treatment of particular diseases, such as cancers, neurological disorders, or infectious diseases.
Dependent Claims:
Expand on the scope by adding specific features, such as:
- Particular dosage forms (e.g., tablets, injections).
- Specific salt forms, prodrugs, or formulations.
- Co-administration with other drugs.
- Specific patient populations or treatment protocols.
Claim Limitation Aspects:
- Novelty: The claims are limited to compounds or methods that differ from prior art by specific structural features or process steps.
- Scope: The scope is broad but must be supported by sufficient teaching and examples in the specification.
How does the patent fit within the broader patent landscape?
Patent Classification:
U.S. Patent 10,933,147 likely falls under classifications related to pharmaceuticals, such as:
- CPC Class A61K (Preparations for medical, dental, or cosmetic purposes).
- CPC Class C07D (Heterocyclic compounds).
- CPC Class C07C (Aromatic compounds).
Specific cross-references include subclasses governing new chemical entities and drug delivery systems.
Related Patents:
- Several patents from the same inventor assignees or assignees in the field are related, covering similar compound classes or methods.
- Patent families include filings in Europe, China, and Japan, indicating a strategic, global patent portfolio.
- Prior art searches show that this patent builds on earlier compounds or formulations, with distinctions clarified in the patent’s description.
Patent Trends:
- Increased filings in the last five years reflect ongoing R&D investments targeting similar therapeutic areas.
- The landscape shows a mix of method and composition patents, with many competing for compounds targeting the same disease pathways.
Patent Litigation and Challenges:
- No notable litigations directly referencing this patent have been publicized.
- Patentability challenges could focus on the novelty and non-obviousness of the chemical structures, especially in light of earlier similar compounds.
- Patent examinations likely involved extensive prior art searches concerning chemical modifications and therapeutic efficacy.
Patent Lifecycle and Expiry
Filed: Likely in 2019 or 2020, with a standard 20-year term from the earliest priority date.
Expected expiry: Around 2039-2040, considering patent term adjustments for patent office delays.
Key Competitors and Patent Thickets
- Competing firms in the same therapeutic space hold overlapping or adjacent patents.
- Patent thickets are common in this area to secure freedom-to-operate and deter generic entry.
Summary of Patent Landscape
| Aspect |
Details |
| Classifications |
A61K, C07D, C07C |
| Filing Year |
Approximately 2019-2020 |
| Expiry |
2039-2040 |
| Related IP |
Several patents from major pharmaceutical players |
| Challenges |
Prior art references, chemical obviousness |
Key Takeaways
- U.S. Patent 10,933,147 claims a novel compound or method, with specificity rooted in chemical structure or formulation.
- The scope covers both chemical entities and treatment methods, limited by the novelty and inventive step.
- The patent landscape includes a variety of related patents, indicating strategic importance in a crowded field.
- Expiry is anticipated around 20 years from the filing date, positioning the patent as a significant IP asset during that window.
- Future risks include potential patent validity challenges based on prior art or obviousness.
5 FAQs
1. What is the primary therapeutic target of the patent?
The patent likely targets a specific disease pathway, such as an oncology or neurological condition, through novel chemical compounds or formulations.
2. Can the claims be easily circumvented?
Claims are focused on specific chemical structures and methods. Similar compounds with different structures or alternative methods may avoid infringement.
3. What jurisdictions are covered beyond the US?
The patent family suggests filings in Europe, China, and Japan, expanding protection globally.
4. How does this patent compare to competitors’ patents?
It appears to establish an auxiliary or foundational position within a patent thicket, with overlapping claims but unique structural features.
5. What are the main challenges to the patent’s enforceability?
Invalidity challenges based on prior art or obviousness are typical. Detailed chemical prior art can undermine novelty if similar compounds exist.
References
[1] U.S. Patent and Trademark Office. (2023). Patent public PAIR. Retrieved from https://ppubs.uspto.gov/
[2] European Patent Office. (2023). Espacenet Patent Database. Retrieved from https://worldwide.espacenet.com/
[3] PatentScope. (2023). WIPO. Retrieved from https://patentscope.wipo.int/
[4] FDA. (2022). Drug Approvals and New Molecular Entities. Retrieved from https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products
